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Contribution of Piezo2 
to endothelium-dependent pain
Luiz F. Ferrari, Oliver Bogen, Paul Green and Jon D. Levine*
Abstract 
Background: We evaluated the role of a mechanically-gated ion channel, Piezo2, in mechanical stimulation-induced 
enhancement of hyperalgesia produced by the pronociceptive vasoactive mediator endothelin-1, an innocuous 
mechanical stimulus-induced enhancement of hyperalgesia that is vascular endothelial cell dependent. We also 
evaluated its role in a preclinical model of a vascular endothelial cell dependent painful peripheral neuropathy.
Results: The local administration of oligodeoxynucleotides antisense to Piezo2 mRNA, at the site of nociceptive test-
ing in the rat’s hind paw, but not intrathecally at the central terminal of the nociceptor, prevented innocuous stimu-
lus-induced enhancement of hyperalgesia produced by endothelin-1 (100 ng). The mechanical hyperalgesia induced 
by oxaliplatin (2 mg/kg. i.v.), which was inhibited by impairing endothelial cell function, was similarly attenuated by 
local injection of the Piezo2 antisense. Polymerase chain reaction analysis demonstrated for the first time the presence 
of Piezo2 mRNA in endothelial cells.
Conclusions: These results support the hypothesis that Piezo2 is a mechano-transducer in the endothelial cell 
where it contributes to stimulus-dependent hyperalgesia, and a model of chemotherapy-induced painful peripheral 
neuropathy.
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Background
We have recently described a vascular endothelial cell-
dependent, innocuous mechanical stimulus-induced 
enhancement of mechanical hyperalgesia that occurs 
following the administration of two potent vasoactive 
pronociceptive mediators, endothelin-1 and epineph-
rine [1, 2], but not other pronociceptive mediators (e.g., 
prostaglandin E2, nerve growth factor and tumor necrosis 
factor alpha) [1], at the site of nociceptive testing in the 
hind paw. In this innocuous stimulus-induced enhance-
ment of mechanical hyperalgesia, after the local intra-
dermal administration of endothelin-1 or epinephrine, 
repeated application of an innocuous mechanical stimu-
lus produces a stepwise lowering of mechanical nocic-
eptive threshold. Subsequent experiments demonstrated 
that endothelin-1 and epinephrine act at their cognate 
receptors on the endothelial cell and that following their 
administration at the site of nociceptive testing, innocu-
ous mechanical stimuli induce the release of ATP from 
the endothelial cell, which in turn acts at P2X2/3, a ligand-
gated ion channel receptor, on the peripheral terminal of 
the primary afferent nociceptor, to enhance mechanical 
hyperalgesia [3, 4].
A key feature of this stimulus-dependent hyperalge-
sia that remains to be established is the molecular basis 
of the transduction process for innocuous mechanical 
stimuli in the endothelial cell. Patapoutian and colleagues 
cloned a family of mechano-transducing ion channels, 
the Piezos that are gated by innocuous mechanical stim-
uli [5, 6]. More recently Patapoutian [7, 8], Gu [9] and 
colleagues, have demonstrated a key role of Piezo2 chan-
nels in the mechano-transduction process in Merkel cell-
mediated touch. In the present study we provide evidence 
that Piezo2 contributes to endothelin-1-induced stimu-
lus-dependent enhancement of mechanical hyperalge-
sia. In addition, since some neuropathic pain syndromes, 
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such as that induced by oxaliplatin, affect vascular func-
tion [10–12], and vascular endothelium has a function in 
peripheral pain mechanisms [3, 4], we also evaluated the 
role of the endothelium and Piezo2 in a model of painful 
peripheral neuropathy produced by the cancer chemo-
therapy drug oxaliplatin.
Results
Contribution of peripheral Piezo2
To evaluate the role of the Piezo2 channel in stimulus-
dependent hyperalgesia, we injected a mixture of 3 oli-
godeoxynucleotide (ODN) sequences antisense against 
Piezo2 mRNA (see “Methods”), or of their mismatch 
ODNs, at the site of nociceptive testing on the dorsum 
of the rat’s hind paw (20 μg/1 μl for each sequence, added 
to 2 μl of oligofectamine, in a total volume of 5 μl, intra-
dermally). Endothelin-1 (100 ng) was then injected at the 
same site, 6  h later. The mechanical nociceptive thresh-
old was measured just prior to injection of endothelin-1 
and then at 5-min intervals (X4), starting 15  min after 
the injection of endothelin-1. The administration of the 
Piezo2 antisense mixture, compared to mismatch, all but 
eliminated the sequential decrease in nociceptive thresh-
old produced by each subsequent mechanical stimulus; 
that is, it eliminated stimulus-dependent hyperalgesia 
(Fig. 1). The residual hyperalgesia detected at the first test 
of nociceptive threshold is due to the action of endothe-
lin-1 at the ETA/B receptor(s) on the peripheral termi-
nal of the nociceptor innervating the site of nociceptive 
testing [3]. These data support a role for Piezo2 as a 
mechano-transducer in endothelin-1-induced stimulus-
dependent hyperalgesia.
Non‑neuronal location of peripheral Piezo2
The Piezo2 channel has been demonstrated to be present 
in dorsal root ganglion (DRG) neurons [5]. Therefore, 
to rule out the possibility that the effect of intradermal 
Piezo2 ODN antisense was due to its uptake into the 
peripheral terminal of primary afferent nociceptors in 
the skin, followed by its transport to the cell body, and 
the subsequent down regulation of Piezo2 protein in the 
peripheral terminals of the primary afferents in the skin, 
we administered the same ODNs, antisense or mismatch, 
via the spinal intrathecal route of administration. How-
ever, unlike the intradermal administration of the Piezo2 
ODN antisense, the intrathecal administration of the 
ODN antisense mixture against Piezo2 mRNA failed to 
attenuate stimulus-dependent hyperalgesia (Fig. 2). These 
findings support the suggestion that the ability of local 
peripheral administration of antisense to Piezo2 mRNA 
Fig. 1 Role of Piezo2 in peripheral tissue in innocuous stimulus-induced enhancement of the mechanical hyperalgesia induced by endothelin-1. 
Rats received an intradermal injection of a combination of 3 sequences of ODN mismatch (MM, open symbols) or antisense (AS, dark symbols) 
against Piezo2 mRNA (20 μg of each sequence/μl, added to 2 μl of oligofectamine; total volume: 5 μl) on the dorsum of the hind paw. 6 h later, 
endothelin-1 (100 ng) was injected at the same site. At the same site, the paws then were submitted to 4 mechanical stimuli, 5 min apart from each 
other, starting 15 min after endothelin-1 injection. In the paws pretreated with local injection of ODN AS, compared to ODN MM, the decrease in 
the nociceptive threshold subsequent to the mechanical stimulations was significantly attenuated, indicating a role of peripheral Piezo2 channels 
in stimulus-dependent hyperalgesia. (F1,10 = 140.7; **p < 0.0061 and ****p < 0.0001, when the groups are compared at each reading, two-way 
repeated measures ANOVA followed by Bonferroni’s post hoc test; N = 6 paws per group). a Shows the mechanical nociceptive threshold, in grams, 
after each stimulation, starting 15 min post-endothelin-1 injection; in b, the reduction in the mechanical threshold after each stimulation, when 
compared to the baseline, is represented as percentage change
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to attenuate stimulus-dependent hyperalgesia, is not 
due to its action on the primary afferent nociceptor, but 
rather by its action on Piezo2 containing cells in the skin.
Role of Piezo2 in oxaliplatin‑induced neuropathy
In a preliminary experiment we observed that octo-
xynol-9, which attenuates endothelial cell function 
[13–15], attenuates mechanical hyperalgesia in oxali-
platin chemotherapy-induced painful peripheral neu-
ropathy (unpublished data). To confirm a contribution of 
endothelial cells in oxaliplatin-induced painful peripheral 
neuropathy and evaluate for a role of Piezo2, we tested 
the effect of octoxynol-9 and Piezo2 antisense in our pre-
viously described model of oxaliplatin-induced hyper-
algesia [16]. Intravenous injection of oxaliplatin (2  mg/
kg) induced mechanical hyperalgesia that was signifi-
cantly inhibited by intravenous injection of octoxynol-9 
(Fig.  3a), which has been shown to impair endothe-
lial function [13–15], implicating the endothelial cell 
in this model of cancer chemotherapy-induced painful 
peripheral neuropathy. It was not, however, possible 
to determine if there was a contribution of the mecha-
nism underlying stimulus-dependent hyperalgesia or 
an alternative endothelial cell mechanism to the oxali-
platin-induced hyperalgesia, probably due to the degree 
of ongoing mechanical hyperalgesia. Hence, to evaluate 
if stimulus-dependent hyperalgesia contributes to the 
oxaliplatin-induced mechanical hyperalgesia, we attenu-
ated its candidate mechano-transducer, Piezo2, using the 
local injection of the ODNs antisense to Piezo2 mRNA. 
We observed that the ODN antisense against Piezo2 
mRNA injected at the site of nociceptive testing on the 
dorsum of the hind paw, strongly attenuated the mechan-
ical hyperalgesia produced by oxaliplatin (Fig. 3b), com-
patible with the suggestion that the Piezo2 channel in 
endothelial cells plays a role in this form of neuropathic 
pain.
Piezo2 mRNA in rat endothelial cells
While the expression of Piezo2 in DRG neurons as well 
as in cells in the skin such as Merkel cells has been previ-
ously shown [7, 8, 17], its presence in the endothelial cell 
has not been studied. However, if Piezo2 plays a role in 
stimulus-dependent hyperalgesia, it must be expressed in 
the endothelial cell. Therefore, we determined if Piezo2 
transcripts are present in rat endothelial cells, using PCR 
analysis on RNA extracts from rat aortic endothelial 
cells. As observed in Fig. 4, Piezo2 was detected in RNA 
extracts derived from cultured rat aortic endothelial cells.
Discussion
While vascular pain syndromes are common [18–25] 
they are, unfortunately, often refractory to currently 
available analgesic therapy. This is due, at least in part, 
to a relative lack of understanding of the mechanisms 
of vascular pain, in comparison to pain arising from 
other structures. We recently described a novel, vascular 
endothelial cell-dependent mechanism for pain, a form 
of innocuous mechanical stimulation-induced release of 
pronociceptive mediators from endothelial cells that in 
turn sensitize nociceptors to intense mechanical stimuli, 
producing mechanical hyperalgesia. We have referred 
to this endothelial cell contribution to peripheral pain 
mechanisms as stimulus-dependent hyperalgesia [1, 4, 
26]. In stimulus-dependent hyperalgesia, pronociceptive 
vasoactive substances such as endothelin-1 and epineph-
rine, acting at their cognate receptors on the endothelial 
cell, sensitize this cell to innocuous mechanical stimulus-
induced release of a pronociceptive mediator, adenosine 
triphosphate (ATP) that in turn can act at P2X2/3 recep-
tors to sensitize the peripheral terminal of the nociceptor, 
the mechanism underlying primary hyperalgesia [3, 4]. 
Importantly, with respect to the transduction properties 
Fig. 2 Piezo2 in sensory neurons innervating the skin do not play a 
role in endothelin-1-induced stimulus-dependent hyperalgesia. Rats 
were treated for 3 consecutive days with intrathecal injection of the 
combination of 3 sequences of ODN antisense (AS, dark symbols) 
or mismatch (MM, open symbols) against Piezo2 mRNA. On the 4th 
day, endothelin-1 (100 ng) was injected on the dorsum of the hind 
paw. Four mechanical stimuli, 5 min apart from each other, were 
performed, starting 15 min after endothelin-1 injection. No difference 
was observed between the groups in the decrease in the nocicep-
tive threshold subsequent to the mechanical stimuli, indicating that 
Piezo2 channels in the DRG neurons are not involved in stimulus-
dependent hyperalgesia induced by endothelin-1. (p = 0.9895, 
non-significant, when the groups are compared, two-way repeated 
measures ANOVA followed by Bonferroni’s post hoc test; N = 6 paws 
per group)
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of Piezo2 [7–9], innocuous stimuli are able to act at the 
endothelial cell to produce the ATP released in stimulus-
dependent hyperalgesia [4].
We recently demonstrated a role of the vascu-
lar endothelial cell in preclinical models of persis-
tent pain, including that induced by occupational 
exposure to intense low frequency high amplitude vibra-
tion and eccentric exercise [3] and in cancer chemother-
apy-induced painful peripheral neuropathy produced by 
administration of oxaliplatin (unpublished data), a chem-
otherapy drug used to treat colorectal cancer [27–29]. 
The present study explored one of the key missing ele-
ments of the mechanism underlying stimulus-depend-
ent hyperalgesia, the molecular basis of the mechanical 
transducer involved in the induction of the release of 
pronociceptive mediators from the endothelial cell by 
innocuous mechanical stimuli.
In the present experiments we tested the hypothesis 
that Piezo2, a mechanically-gated ion channel that is acti-
vated by relatively innocuous mechanical stimuli [8, 30, 
31], could be the mechano-transducer in the endothe-
lial cell that mediates the innocuous stimulus-induced 
enhancement of mechanical hyperalgesia induced by 
endothelin-1. In support of this hypothesis we found 
that ODNs antisense to Piezo2 mRNA, when injected 
intradermally at the site of nociceptive testing, but not 
intrathecally, at the site of the central terminal of the pri-
mary afferent nociceptor, which would be expected to 
attenuate expression of Piezo2 in the peripheral terminal 
of the nociceptor, eliminated stimulus-dependent hyper-
algesia. These results support a role for Piezo2, in a cell in 
the skin, in stimulus-dependent hyperalgesia.
While there could be a cell in the skin, other than the 
endothelial cell, that contains Piezo2, which mediates 
Fig. 3 Role of the vascular endothelium and Piezo2 in peripheral tissue in oxaliplatin-induced neuropathic pain. a Rats that had been treated with a 
single intravenous injection of oxaliplatin (2 mg/kg) received, 48 h later, octoxynol-9 (0.5 % solution, injected intravenously; gray bar). The mechani-
cal nociceptive thresholds were evaluated, by the Randall-Sellitto paw withdrawal test, 30 min after octoxynol-9 injection. We observed significant 
attenuation of the mechanical hyperalgesia induced by oxaliplatin in rats treated with octoxynol-9 when compared to a control group (white bar) 
(t10 = 6.923; ****p < 0.0001, when both groups are compared, Student’s t test), indicating a role of the endothelium in this model of chemotherapy-
induced neuropathic pain (N = 6 paws per group); b rats received intravenous injection of oxaliplatin (2 mg/kg). 24 h later, the combination of 
3 sequences of ODN mismatch (MM, white bar) or antisense (AS, black bar) against Piezo2 mRNA (20 μg of each sequence/μl, added to 2 μl of 
oligofectamine; total volume: 5 μl) was injected on the dorsum of the hind paw. 6 h later, the paws were submitted to 4 mechanical stimuli, 5 min 
apart from each other. We observed that in the paws treated with local injection of ODN AS, but not of ODN MM, the decrease in the nociceptive 
threshold subsequent to the mechanical stimuli was significantly attenuated, indicating a role of peripheral Piezo2 channels in oxaliplatin-induced 
hyperalgesia. (t10 = 12.38; ****p < 0.0001, when both groups are compared, Student’s t test; N = 6 paws per group)
Fig. 4 Expression of Piezo2 mRNA in endothelial cells. PCR analysis 
of Piezo2 mRNA was performed in extracts obtained from cultured 
rat aortic endothelial cells (RAOEC). cDNA from RAOEC was used 
to analyze whether endothelial cells express Piezo2. The size of the 
Piezo2 amplification product is 278 bp. M DNA—ladder; 1 30 cycles, 
2 35 cycles;  3 40 cycles
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stimulus-dependent hyperalgesia (e.g., Merkel cells [8]), 
the fact that stimulus-dependent hyperalgesia, which is 
eliminated by inhibition of vascular endothelial cell func-
tion [3, 26], is induced by two vasoactive pronociceptive 
mediators, endothelin-1 and epinephrine, whose recep-
tors are present on endothelial cells, and is mediated by 
mechanical stimulus-induced release of pronociceptive 
mediators from the endothelial cell [4], supports the role 
of endothelial cell Piezo2 as the mechano-transducer 
responsible for stimulus-dependent hyperalgesia. How-
ever, since it has not previously been demonstrated that 
Piezo2 is present in endothelial cells, a necessary condi-
tion for endothelial cells to mediate innocuous stimulus-
induced enhancement of endothelin-1 hyperalgesia, we 
examined for the presence of Piezo2 in endothelial cells. 
However, since endothelial cells constitute such a small 
percentage of cells in the skin, being a cellular monolayer 
lining the luminal surface of blood vessels, we addressed 
this question in cultured rat aortic endothelial cells. In 
this pure population of endothelial cells we were able to 
establish the presence of Piezo2 mRNA. To exclude a role 
of Piezo2 in the peripheral terminal of the nociceptor, we 
administered the Piezo2 antisense ODN intrathecally so 
that the only cell in the skin that could be affected by the 
antisense would be the peripheral terminal innervation 
of the sensory fibers the skin. This route of administra-
tion failed to attenuate stimulus-dependent hyperalgesia. 
While the pharmacology of Piezos in general, and Piezo2 
in particular, are still relatively early in development, 
our data do support the suggestion that Piezo2 antago-
nists could be effective in the treatment of endothelial 
cell-dependent vascular pain syndromes. This is impor-
tant since inhibiting ATP-dependent mechanisms, which 
mediate stimulus-dependent hyperalgesia [2–4], might 
have substantial adverse side effects.
Finally, to determine if Piezo2-dependent mechanisms 
in the skin contribute to an endothelial cell dependent 
preclinical pain syndrome, we evaluated the effect of the 
peripheral administration of ODNs antisense to Piezo2 
mRNA in a preclinical model of a cancer chemotherapy-
induced painful peripheral neuropathy, induced by oxali-
platin, which we found in preliminary experiments to be 
endothelial cell dependent. Attenuation of endothelial 
function, with octoxynol-9 or peripheral administration 
of ODN antisense to Piezo2 mRNA, both attenuated 
mechanical hyperalgesia in this model of chemotherapy-
induced painful peripheral neuropathy, without affecting 
baseline paw withdrawal threshold in control rats. Thus, 
it would appear that stimulus-dependent sensitization 
can itself be so sensitized that it produces ongoing nocic-
eptor sensitization in the absence of additional mechani-
cal stimulation.
Conclusions
In summary, in this study we provide evidence that 
Piezo2 can function as a mechano-transducer in the 
endothelial cell, contributing to its role in vascular pain 
mechanisms, as described in the schematic in Fig.  5. 
However, which pain syndromes this mechanism con-
tributes to remains to be established.
Methods
Animals
Experiments were performed on male Sprague–Daw-
ley rats (200–250  g; Charles River). The experimental 
animals were housed three per cage, under a 12 h light/
dark cycle, in a temperature- and humidity-controlled 
environment. Food and water were available to the rats 
ad  libitum. All behavioral nociceptive testing was per-
formed between 9:00 AM and 5:00 PM. Rats were accli-
matized to the experimental environment and behavioral 
procedures before the actual experiments. To acclimate 
rats to the testing environment, they were brought to 
the room in which experiments were to be performed, 
in their home cages, where they were left for 15–30 min. 
After this they were placed in cylindrical transparent 
acrylic restrainers that have side vents that allow exten-
sion of the hind limbs from the restrainer for nociceptive 
testing. Rats were then left undisturbed in the restrainer 
for an additional 15–30  min before nociceptive testing 
was initiated. All experimental protocols were approved 
by the University of California, San Francisco, Com-
mittee on Animal Research, and conformed to National 
Institutes of Health Guidelines for the Care and Use of 
Laboratory Animals. Concerted effort was made to mini-
mize the number of animals used and their suffering.
Nociceptive testing
The nociceptive flexion reflex was quantified with an Ugo 
Basile Analgesymeter® (Stoelting, Chicago, IL, USA), 
which uses a dome-shaped plinth to apply a linearly 
increasing mechanical force to the dorsum of the rat’s 
hind paw. Nociceptive threshold was defined as the force 
in grams at which the animal withdrew its paw. Using our 
previously established protocol for studying innocuous 
stimulus-induced enhancement of mechanical hyperalge-
sia [1, 26], single nociceptive threshold measurements were 
made prior to the intradermal injection of endothelin-1, 
and then 15, 20, 25, and 30 min after its administration. 
Hyperalgesia was defined as a decrease in mechanical noci-
ceptive threshold, here presented as percentage decrease 
from baseline mechanical paw-withdrawal threshold. Each 
paw was treated as an independent measure; both paws of 
the same rat received the same treatment. Each experiment 
was performed on separate groups of rats.
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Drugs and reagents
The following drugs and reagents were used in this study: 
endothelin-1, oxaliplatin, and octoxynol-9, all obtained 
from Sigma-Aldrich (St. Louis, MO, USA). Endothelin-1 
(100 ng) was dissolved in saline and administered intra-
dermally on the dorsum of the hind paw, in a volume of 
5  μl, using a 30-gauge hypodermic needle attached to a 
microsyringe (10  μl; Hamilton, Reno, NV, USA) by a 
short length of polyethylene tubing (PE-10). Oxaliplatin 
(dissolved in saline to a concentration of 2 mg/kg), used 
to induce painful peripheral neuropathy [16, 28, 32], and 
octoxynol-9 (0.5 % solution in saline, at a volume of 1 ml/
kg), used to evaluate the contribution of the endothelium 
to nociceptive mechanisms [4, 13, 14], were administered 
intravenously via tail vein injection, followed by a bolus 
injection of an equal volume of saline before removal of 
the injection needle. Drug doses were selected based on 
the results of our previous studies [3, 4, 16, 33].
ODN antisense sequences against Piezo2 mRNA
Because the endothelial cells that mediate stimulus-
dependent hyperalgesia are a single cell layer thick lin-
ing in the dermal microvasculature, constituting an 
extremely small percentage of cutaneous tissue’s mass, 
we used an approach shown by Wood and colleagues to 
attenuate Piezo2 in more accessible cells, in the nervous 
system of the mouse [34]. In that study a mixture of 3 
different ODN sequences all antisense to Piezo2 mRNA 
was used to attenuate the expression of Piezo2, dem-
onstrating its functional role in sensory neurons [34]. 
Because of species differences between mouse and rat for 
the Piezo2 mRNA nucleotide sequence used by Wood 
and colleagues for their anti-Piezo2 antisense, we gener-
ated 3 nucleotide sequences designed based on the rat 
genome. The 3 sequences for the rat ODNs antisense to 
Piezo2 mRNA are: 5′-CCACCACATAAACACCTGC-3′, 
5′-TTCCTCCTCTTCACTATCCG-3′ and 5′-CCTCAA 
TGGTTTCCGTAGTTC-3′ (Invitrogen, Carlsbad, CA, 
USA), directed against three unique sequences of rat 
Piezo2 mRNA. The corresponding GenBank accession 
number and ODN position within the cDNA sequence 
are XM_255880.8 and 3740–3758, 5617–5636, 6238–
6258, respectively. The ODN mismatch sequences, 
5′-ACATCACACGAACTCCAGC-3′, 5′-GTCATCGTC 
ATCACATTGCG-3′ and 5′-TCTCAGTGCTCTCCAT 
AGGTA-3 correspond to the Piezo2 ODN antisense 
sequences with 6 or 7 bases mismatched (denoted by 
bold letters). To the mixture of the 3 antisense or mis-
match mRNAs, 20  μg in a volume of 1  μl each, 2  μl of 
oligofectamine transfection reagent (Invitrogen) was 
added, completing a total volume of 5  μl, in order to 
facilitate the penetration of the ODNs into the endothe-
lial cells. The ODNs were injected intradermally, on the 
dorsum of the rat’s hind paw. 6 h later endothelin-1 was 
administered at the same site. Of note, regarding the 
direct administration of the ODNs into the skin, the 
critical variable in this method is the half-life of Piezo2 
in the endothelial cell, which is unknown. Among the 
different time points tested, 6  h was found to be long 
enough to observe a significant impact of the ODN anti-
sense in our model. Therefore, we chose this time point 
to be used in the experiments shown in Figs. 1 and 3b. 
In separate groups of rats, the same doses (20 μg each) 
of the 3 ODNs, antisense or mismatch, were adminis-
tered intrathecally. In this case, the ODNs were recon-
stituted in 0.9 % NaCl to a concentration of ~0.35 μg/μl, 
and administered daily for 3 consecutive days before the 
injection of endothelin-1 on the dorsum of the hind paw. 
During each injection, rats were anesthetized with 2.5 % 
isoflurane in 95  % O2. A 30-gauge hypodermic needle 
was then inserted, on the midline, into the subarachnoid 
space, between the L4 and L5 vertebrae. A total of 20 μl 
was slowly injected. The intrathecal site of injection was 
confirmed by a sudden tail flick, a reflex that is evoked 
by subarachnoid space access and bolus injection [35]. 
Animals regained consciousness approximately 1  min 
after the injection. The use of antisense to attenuate the 
expression of proteins in nociceptors, important for 
their role in nociceptor sensitization, is well supported 
by previous studies by others [36–39], as well as our 
group [40–43].
Polymerase chain reaction (PCR)
Total RNA from cultured rat aortic endothelial cells 
(RAOEC, Cell Applications, San Diego, CA, USA) was 
extracted using Trizol reagent (Invitrogen/Thermo 
Fisher Scientific, Waltham, MA, USA) with the Pure-
Link™ RNA mini kit (Ambion/Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s 
instruction. The amount of RNA was determined with 
an UV-spectrophotometer and 1  µg of RNA was used 
for cDNA synthesis using the SuperScript III Platinum 
One-Step quantitative RT-PCR System (Invitrogen/
Thermo Fisher Scientific, Waltham, MA, USA). 10  µl 
of the cDNA were used to analyze for Piezo2 expres-
sion. The PCR-primers used for the amplification of rat 
Piezo2 were: F1: 5′-ACACCATGCTGGTGCTCATC-3′ 
and B1: 5′-AGGGTGGGCTAACCTGTAGA-3′ and 
matched against NCBI database-entry XM_225880. The 
Piezo2 PCR products were electrophoretically separated 
on a 2 % agarose gel and visualized by ethidium bromide 
intercalation.
Statistical analyses
The dependent variable in these experiments was change 
in paw withdrawal threshold, expressed as percentage, or 
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in Fig.  1a also absolute change in grams, from the pre-
treatment baseline threshold. Group data are represented 
as mean ± SEM. Statistical significance was determined 
by two-way repeated-measures ANOVA, followed by 
Bonferroni’s post hoc test, or by Student’s t test (as noted 
in the Figure Legends). p values <0.05 were considered 
statistically significant.
Abbreviations
AS: antisense; DRG: dorsal root ganglion; MM: mismatch; ODN: oligodeoxynu-
cleotide; SEM: standard error of the mean.
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